Information

This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.

Confirm

Key Opinions in Medicine

  • Register
  • Login
Skip to content
  • Home
  • Issues
    • Allergy & Immunology
    • Cardiology
    • Conference
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes & Endocrinology
    • Gastroenterology
    • General Medicine
    • Haematology
    • Hepatology
    • Infectious Diseases
    • Metabolic Disorders
    • Neurology
    • Nursing
    • Obstetrics & Gynaecology
    • Oncology
    • Paediatrics
    • Psychiatry
    • Rheumatology
    • Surgery Insights
    • Urology
  • About
  • Contact
  • Register
  • Login

Fig3_01

Published May 16, 2016 at 664 × 581 in MRGE: lansoprazolo migliora la compliance, l’accettabilità della terapia e il sollievo dei sintomi.
← Previous Next →

Figura 2. Rispetto ai pazienti trattati con omeprazolo, i pazienti assegnati a lansoprazolo hanno riportato percentuali più alte di sollievo persistente dalla pirosi ad ogni valutazione temporale (nella maggior parte dei pazienti dopo 7 giorni di trattamento. p = 0,0287).

Popular Issues

Konkurrenz für den Therapiestandard

MOVICOL® (PEG3350 plus electrolytes): 20 years of evidence-based use

Register

profile Register

Sign up for free access to Wiley’s Key Opinions in Medicine to keep up to date with latest trends and key developments within your specialty area.

Share

Copyright © 2000-2025 by John Wiley & Sons, Inc., or related companies. All rights reserved.
Review our privacy policy. Cookie Preferences.
Web design and marketing agency Leamington Spa